The main reason for this is that it is a good idea to use a lot of the same drugs as the other drugs. Our study found that the application of lipid microspheres wrapped in prostaglandin E 1, treatment for 3 to 4 weeks, can make the symptoms improve and last up to 6 months, the patient’s pain score decreased significantly. 2.Sagarate hydrochloride: It has the effects of inhibiting platelet agglutination and secondary agglutination, inhibiting vasoconstriction, inhibiting vascular smooth muscle cell proliferation and increasing collateral circulation, improving peripheral circulation disorders, and antithrombotic. We used aspirin as a control drug and confirmed that after 1 2 weeks of treatment with sagarin hydrochloride, the pain-free walking distance and the maximum walking distance that can tolerate pain were significantly improved in patients with diabetes combined with P A D. A B I was significantly improved, which was significantly better than the efficacy of aspirin. 3.Cilostazol: It is a phosphodiesterase inhibitor, which has the effect of inhibiting platelet activation and smooth muscle proliferation, dilating blood vessels and lowering blood triglyceride level. The Department of Endocrinology of China-Japan Friendship Hospital gave 35 cases of diabetic patients cilostazol treatment, and it was found that the patients’ lower limb vasculopathy symptoms and signs were significantly improved at 3 months and 6 months after taking the drug. The neuropathy score of the patients decreased significantly and the nerve conduction velocity increased significantly after treatment. For those with combined lower extremity arterial thrombosis or a tendency to form thrombi, low-molecular heparin therapy can be applied. Diabetic patients with combined PA D should take long-term oral aspirin for prophylaxis if there is no contraindication. Encourage walking exercises in mildly ill patients to promote the establishment of collateral circulation and improvement of blood supply to the lower extremities. Surgical treatment: Vascular intervention: In addition to traditional vascular bypass or grafting, more vascular interventional techniques are now available for PAD, such as intravascular ultrasound ablation, deep balloon dilation, and endovascular stenting. Compared with traditional vascular bypass surgery, vascular interventions are less invasive, less bleeding, less expensive to treat and have shorter hospital stays, and are applicable to approximately half of patients with diabetes mellitus combined with PA D. However, overall, there are few studies comparing interventional treatment of diabetes mellitus with conventional vascular bypass, and there is a lack of evidence-based Class A evidence. The limited studies suggest that the immediate treatment outcomes at 6 months to 1 year are similar to those of traditional vascular bypass, but patients treated with vascular bypass have lower rates of amputation and death at 2 years. With advances in hardware and software for vascular interventional techniques, the treatment outcomes will be further improved. Stem cell transplantation as a new treatment for diabetic PAD has been carried out in several hospitals in China and has achieved better clinical results.